ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Georgia » Hematology Oncology

Top Hematology Oncology Prescribers in Georgia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JAYANTHI SRINIVASIAH MD

Hematology Oncology

6,060

$1.48M

507
360 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

21%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$244
Average prescription price

Avg: $325

ANTHONY ONYEGBULA D.O.

Hematology Oncology

5,016

$242K

279
139 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

23%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 17%

$48
Average prescription price

Avg: $325

CARLOS FRANCO MD

Hematology Oncology

4,274

$945K

525
366 are 65+

13%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 17%

$221
Average prescription price

Avg: $325

ANTONIO MORAN M.D.

Hematology Oncology

4,151

$875K

316
241 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

22%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 17%

$211
Average prescription price

Avg: $325

JOSE TONGOL MD

Hematology Oncology

3,568

$1.4M

419
267 are 65+

22%
patients receiving schedule two controlled substances

Avg: 18%

22%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 17%

$393
Average prescription price

Avg: $325

THOMAS NEAL MD

Hematology Oncology

3,542

$1.09M

463
297 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

16%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$309
Average prescription price

Avg: $325

ANIL DESAI MD

Hematology Oncology

3,532

$284K

264
143 are 65+

8%
patients receiving schedule two controlled substances

Avg: 18%

16%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$81
Average prescription price

Avg: $325

DOUGLAS COLLINS M.D.

Hematology Oncology

3,372

$965K

269
168 are 65+

39%
patients receiving schedule two controlled substances

Avg: 18%

16%
patients receiving schedule three controlled substances

Avg: 14%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$286
Average prescription price

Avg: $325

RICHARD CARTER MD

Hematology Oncology

3,222

$539K

328
249 are 65+

15%
patients receiving schedule two controlled substances

Avg: 18%

27%
patients receiving schedule three controlled substances

Avg: 14%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

11%
prescriptions for brand name drugs

Avg: 17%

$167
Average prescription price

Avg: $325

STEPHEN SZABO MD

Hematology Oncology

3,203

$1.38M

388
302 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

16%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 17%

$431
Average prescription price

Avg: $325

PHILLIP ROBERTS MD

Hematology Oncology

3,084

$178K

197
144 are 65+

17%
patients receiving schedule two controlled substances

Avg: 18%

12%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 17%

$58
Average prescription price

Avg: $325

JAMES SPLICHAL M.D.

Hematology Oncology

2,993

$712K

327
253 are 65+

26%
patients receiving schedule two controlled substances

Avg: 18%

27%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

9%
prescriptions for brand name drugs

Avg: 17%

$238
Average prescription price

Avg: $325

AKINWOLE AWUJO MD

Hematology Oncology

2,985

$220K

109
70 are 65+

24%
patients receiving schedule two controlled substances

Avg: 18%

16%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 17%

$74
Average prescription price

Avg: $325

LAWRENCE GYNTHER M.D.

Hematology Oncology

2,910

$837K

235
194 are 65+

12%
patients receiving schedule two controlled substances

Avg: 18%

18%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$288
Average prescription price

Avg: $325

ANDRE KALLAB M.D.

Hematology Oncology

2,876

$511K

268
230 are 65+

12%
patients receiving schedule two controlled substances

Avg: 18%

12%
patients receiving schedule three controlled substances

Avg: 14%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 17%

$178
Average prescription price

Avg: $325

WILLIAM WHALEY MD

Hematology Oncology

2,853

$391K

298
258 are 65+

7%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

33%
prescriptions for brand name drugs

Avg: 17%

$137
Average prescription price

Avg: $325

ASIT JHA MD

Hematology Oncology

2,835

$627K

279
198 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

18%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 17%

$221
Average prescription price

Avg: $325

SALIM OSTA M.D.

Hematology Oncology

2,758

$267K

122
87 are 65+

12%
patients receiving schedule two controlled substances

Avg: 18%

21%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 17%

$97
Average prescription price

Avg: $325

ABDULLAH KUTLAR MD

Hematology Oncology

2,654

$517K

146
0 are 65+

59%
patients receiving schedule two controlled substances

Avg: 18%

47%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 17%

$195
Average prescription price

Avg: $325

JENNIFER JONES MD

Hematology Oncology

2,594

$320K

256
193 are 65+

20%
patients receiving schedule two controlled substances

Avg: 18%

10%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$123
Average prescription price

Avg: $325

RAO MORAVINENI MD

Hematology Oncology

2,576

$530K

259
196 are 65+

23%
patients receiving schedule two controlled substances

Avg: 18%

21%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 17%

$206
Average prescription price

Avg: $325

THOMAS SEAY MD

Hematology Oncology

2,494

$1.08M

325
285 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 14%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$433
Average prescription price

Avg: $325

GENA VOLAS-REDD MD

Hematology Oncology

2,491

$480K

317
251 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 17%

$193
Average prescription price

Avg: $325

ROBERT KRYWICKI MD

Hematology Oncology

2,240

$600K

242
155 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

19%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 17%

$268
Average prescription price

Avg: $325

JONATHAN BENDER M.D.

Hematology Oncology

2,238

$761K

219
180 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

14%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 17%

$340
Average prescription price

Avg: $325

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank